Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering
We employed CD16 as a biomarker to identify and select Vδ2 T cell PBMC donors. CD16 high Vδ2 T cells were then engineered with a Mesothelin-targeted chimeric antigen receptor and soluble IL-15 for the treatment of ovarian cancers